Public Announcement
Board Nominations Now Open: Digital Therapeutics Alliance Seeks Visionary Leaders to Represent the Diverse Membership and Global Ecosystem”
Digital Therapeutics Alliance (DTA), the leading global non-profit trade association for digital therapeutics (DTx), today announced plans to expand its Board of Directors in 2024 and 2025 to support the organization’s continued growth and evolution.
In 2024, the DTA Board will expand from its current 7 members to 10 members, plus the CEO. In 2025, the Board will further increase to 12 members, plus the CEO as a voting ex-officio member of the board. These additions will broaden the Board’s expertise and perspectives, enhancing governance and strategic leadership as the digital therapeutics industry matures.
“As digital therapeutics gain mainstream adoption, it is crucial that DTA’s leadership represents the diversity of our member organizations driving this healthcare revolution,” said Andy Molnar, DTA CEO. “Expanding our Board will allow greater representation to inform DTA’s mission of enabling patient access to high-quality, evidence-based digital therapeutics.”
DTA is seeking nominations from current members for the 2024 Board of Directors through October 13, 2023. Nominees should be senior executives with demonstrated strategy, board, and governance experience in digital health and commitment to DTA’s vision. Ideal candidates will contribute complementary knowledge across healthcare, technology and policy.
A Nomination Committee will review applications and propose candidates in November based on criteria such as leadership experience, subject matter expertise, and ability to fulfill Board member responsibilities. DTA’s industry membership will vote on final Board member selections in December.
New Board members will serve 3-year terms beginning in 2024. They will help shape DTA’s strategic direction, provide financial oversight, and drive the adoption of clinically-validated digital therapeutics worldwide.
For details on DTA’s Board nomination process, criteria, and application questions may be directed to Andy Molnar.